ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

LENZ LENZ Therapeutics Inc

18.06
-0.26 (-1.42%)
20 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
LENZ Therapeutics Inc NASDAQ:LENZ NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.26 -1.42% 18.06 15.00 23.87 18.75 17.84 18.38 240,161 22:30:00

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

01/05/2024 9:01pm

GlobeNewswire Inc.


LENZ Therapeutics (NASDAQ:LENZ)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more LENZ Therapeutics Charts.

LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 8, 2024 at 4:30 p.m. ET to report its first quarter 2024 financial results and provide a business update.

The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.

About LENZ TherapeuticsLENZ Therapeutics is a late clinical-stage biopharmaceutical company focused on the development and commercialization of the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. LENZ’s product candidates, LNZ100 is a preservative-free, single-use, once-daily eye drops containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY trials as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day.” LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.

Contacts:

Dan Chevallard LENZ TherapeuticsIR@LENZ-Tx.com

Janhavi MohiteStern Investor Relations, Inc.janhavi.mohite@sternir.com

1 Year LENZ Therapeutics Chart

1 Year LENZ Therapeutics Chart

1 Month LENZ Therapeutics Chart

1 Month LENZ Therapeutics Chart